Humacyte Forecasts $1.34M Q4 Revenue, Sees 855% Upside to $7.86 Target
Humacyte’s Q4 2025 revenue is projected at $1.34 million with EPS of -$0.13, following a Q3 miss of $0.75 million revenue and an EPS beat of -$0.11 per share. Analysts place a one-year target of $7.86 (implying 855% upside) and maintain an “Outperform” consensus across seven brokerages.
1. Q4 2025 Estimate Details
Consensus revenue for Q4 2025 stands at $1.34 million with EPS forecast of -$0.13 per share. Full-year 2025 revenue and EPS estimates remain steady at $2.83 million and -$0.31, while 2026 projections call for $23 million in revenue and -$0.47 EPS.
2. Q3 2025 Performance Recap
In Q3 2025, Humacyte reported $0.75 million in revenue, missing the $0.92 million estimate by 18.3%, while EPS of -$0.11 topped the -$0.16 forecast by 30.4%. Shares declined 2.34% the day after the results were released.
3. Analyst Price Targets and Consensus Rating
Seven analysts set an average one-year price target of $7.86, ranging from $3.00 to $25.00, implying 855% upside from the current $0.82. Brokerages maintain an “Outperform” rating with an average score of 2.0, and a GF Value estimate of $0.00 suggests downside risk.